Loading
Leukaemia specialist heading haematology and oncology at University Hospital Frankfurt and co-author of the pivotal RATIFY midostaurin trial.
Hubert Serve is Director of the Department of Internal Medicine 2 (Hematology/Oncology) at University Hospital Frankfurt and a member of the UCT Frankfurt directorate. His research on FLT3 signalling in acute myeloid leukaemia contributed to the development of FLT3 inhibitors, including the international RATIFY trial of midostaurin published in the New England Journal of Medicine in 2017.
| Title | Journal | Year |
|---|---|---|
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | New England Journal of Medicine | 2017 |
Shares University Cancer Center Frankfurt (UCT), Acute myeloid leukaemia and the tags leadership, clinician-scientist, haematology.
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia, haematology.
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia, haematology.
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia, haematology.
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia, haematology.
Shares Acute myeloid leukaemia and the tags clinician-scientist, leukaemia, haematology.
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, haematology.
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia.